Clinical pharmacology of recombinant cytokines;Pharmacologie clinique des cytokines recombinantes

Therapie

Volumn 55, Issue 1, 2000, Pages 155-164

  Rouveix, B ^a   Giroud, J P ^a  

^a Institut Cochin   (France)

Author keywords

Cytokines; Inflammatory diseases; Interferons

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ANTIBODY; CYTOCHROME P450; CYTOKINE; INTERFERON; NEOPTERIN; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 2;

CANCER; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; INFECTION; PHARMACOKINETICS; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR OCCUPANCY;

ANIMALS; CYTOKINES; HUMANS; RECOMBINANT PROTEINS;

EID: 0034105181     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (49)

1. Anderson PM, Sorenson MA. Effects of route and formulation on clinical pharmacokinetics of interleukine. Clin Pharmacokinet 1994; 27: 19-31.
2. Whittington R, Faulds D. Interleukin 2: a review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 1993; 46: 446-514.
3. Piscitelli SC, Reiss WG, Figg WD, Petros WP. Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations. Clin Pharmacokinet 1997; 32: 368-381.
4. Bienvenu J, Coulon L, Doche C et al. Analytical performances of commercial ELISA-kits for IL-2, IL-6 and TNF-α. A WHO study. Eur Cytokine Netw 1993; 4: 447-451.
5. Aziz N, Nishanian P, Mitsuyasu R et al. Variables that affect assays for plasma cytokines and soluble activation markers. Clin Diag Lab Immunol 1999; 6: 89-95.
6. Mayer P, Valent P, Schmidt G et al. The in vivo effects of recombinant human interleukin-3: demonstration of basophil differentiation factor, histamine producing activity, and priming of GM-CSF-responsive progenitors in non human primates. Blood 1989; 74: 613-621.
7. Willemze R, Fenaux P, Gerhartz H et al. A randomized phase I/II multicenter study of rhIL-3 in patients with myelodysplastic syndromes at relatively low risk of developing leukemia. Blood 1992; 80 (suppl. 1): 86a.
8. Dempster AM. Pharmacological testing of recombinant human erythropoietin: implications for other biotechnology products. Drug Develop Res 1995; 35: 173-178.
9. Zbinden G. Safety evaluation of biotechnology products. Drug Safety 1990; 5 (suppl. 1): 58-64.
10. Wing E-J, Magee D-M, Whiteside T et al. Recombinant human granulocyte macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor-α and interferon in cancer patients. Blood 1989; 73: 643-646.
11. Siegel JP, Puri PK. Inlerleukin-2 toxicity. J Clin Oncol 1991; 9: 694-704.
12. Aulitzky WE, Schuler M, Peschel C, Huber C. Interleukins. Clinical pharmacology and therapeutic use. Drugs 1994; 48: 667-677.
13. Bocci V. Interleukins: clinical pharmacokinetics and practical implications. Clin Pharmacokinet 1991; 21: 274-284.
14. Zoon K-C, Arnheiter H. Studies of the interferon receptors. Pharmacol Ther 1984; 24: 259-278.
15. Schofield JR, Robinson WA, Murphy JR, Rovira DK. Low doses of interféron α are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med 1994; 121: 736-744.
16. Clark MA, Williams JF, Gottschall PE, Wecker L. Effetcts of phenobarbital and interleukin-6 on cytochrome P450B1 and 2B2 in cultured rat hepatocytes. Biochem Pharmacol 1996; 51: 701-706.
17. Abdel-Razzak Z, Loyer P, Fautrel A et al. Cytokines down-regulate expression of major cytochrome-P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993; 44: 707-715.
18. Reiss W, Piscitelli SC. Drug-cytokine interactions mechanisms and clinical implications. BioDrugs 1998; 9: 389-395.
19. Brockmeyer NH, Barthel B, Merlins L, Goos M. Changes of antipyrine pharmacokinetics during influenza and after administration of interferon-α and -β. Inter J Clin Pharmacol Ther 1998; 36: 309-311.
20. Piscitelli SC, Vogel S, Figg WD et al. Alteration in indinavir clearance during interlenkin 2 infusions in patients infected with the human immunodeficiency virus. Pharmacotherapy 1998; 18: 1212-1216.
21. Reiners Jr JJ, Cantu AR, Rupp TA. Coordinate modulation of murine hepatic xanthine oxidase activity and the cytochrome P-450 system by interferons. J Interferon Res 1990; 10: 109-118.
22. Talmadge JE, Hartmann D Optimization of an immunotherapeutic protocol with poly (I, C)-LC. J. Biol Response Mod 1986; 70: 171-182.
23. Hawkins MJ, Hoth DF, Wittes RE Clinical development of biological response modifiers: comparison with cytotoxic drugs. Sem Oncol 1986; 13: 132-140.
24. Creekmore SP, Urba WJ, Longo DL. Strategies for clinical monitoring of therapeutic trials. In: Rose NR, De Macario EC, Fahey JL et al., eds. Manual of Clinical Laboratory Immunology. Washington DC, American Society of Microbiology, 1992: 915-922.
25. Maluish A-E, Urba W-J, Longo D-L et al. The determination of an immunologically active dose of interferon-gamma in patients with melanoma. J Clin Oncol 1988; 6: 434-445.
26. Witt PL, Storer BE, Bryan GT et al. Pharmacodynamics and biological response in vivo after single and multiple doses of interferon-β. J Immunother 1993; 13: 191-200.
27. Smith KA. Lowest dose interleukin-2 immunotherapy. Blood 1993; 81: 1414-1423.
28. Stadler WM, Vogelzang NJ. Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma. Semin Oncol 1995; 22: 67-73.
29. Abraham PA, St Peter WL, Redickill KA, Halstenson CE. Controversies in determination of epoetin (recombinant human erythropoietin) dosage. Clin Pharmacokinet 1992; 22: 409-415.
30. Talmadge JE, Tribble HR, Pennington RW et al. Immunomodulatory and immunotherapeutic properties of recombinant gamma interferon and recombinant tumor necrosis factor in mice. Cancer Res 1987; 47: 2563-2570.
31. Edwards BS, Merritt JA, Fuhlbrigge RC et al. Low doses of interferon alpha result in more effective clinical natural killer cell activation. J Clin Invest 1985; 75: 1908-2191.
32. Veenhof C, De Wit R, Taal B et al. A dose-escalation study of recombinant interferon in patients with metastatic carcinoid tumors. Eur J Cancer 1992; 28: 75-78.
33. Tomlinson E. Control of the biological dispersion of therapeutic proteins. In: Hook JB, Poste G, eds. Protein Design and the Development of New Therapeutics and Vaccine. New York: Plenum Press 1990: 331-357.
34. Talmadge JE. Clinical pharmacology of recombinant proteins. J Pharm Pharmacol 1992; 44 (snppl. 1): 195-197.
35. Talmadge JE, Phillips H, Schindler H et al. Systematic preclinical study on the therapeutic properties of recombinant human interleukin-2 for the treatment of metastatic disease. Cancer Res 1987; 47: 5725-2732.
36. Caliguri MA, Murray C, Robertson MJ et al. Selective modulation of human natural killer cell in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest 1993; 91: 123-132.
37. Leahy MG, Pittfield D, Popert S et al. Phase I study comparing continuous infusion of recombinant interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 1992; 10: 1119-1123.
38. MacDoucall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet 1991; 20: 99-113.
39. Beller U, Chachoua A, Speyer J-L et al. Phase 1b study of low dose intraperitoneal recombinant interleukine in patients with refractory advanced ovarian cancer: rational and preliminary report. Gynecol Oncol 1989; 34: 407-441.
40. Konrad MW, Hemstreet G, Hersh EM et al. Pharmacokinetics of recombiant interleukin 2 in humans. Cancer Res 1990; 50: 2009-2017.
41. Huland E, Huland H, Heinzer H. Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinome. J Urol 1992; 147: 344-348.
42. Rollwagen FM, Bagar S. Oral cytokine administration. Trends Immunol Today 1996;17: 548-549.
43. Todd PA, Goa KL. Interferon gamma. A review of its pharmacology and therapeutic potential in chronic granulomatous disease. Drugs 1992; 43: 111-122.
44. Woodman RC, Erickson RW, Rae J et al. Prolonged recombinant interferon gamma therapy in chronic granulomatous disease: evidence against enhanced neutrophil oxidase activity. Blood 1992; 79: 1558-1562.
45. Rouveix B, Blin O. Pharmacological basis of immunotherapy in auto-immune diseases. Clin Neuropharmacol 1993; 16: 104-112.
46. Billard C, Ferbus D. Predicting responses to interferon. Lancet 1990; 336: 1388-1389.
47. Heaton KM, Grimm EA. Cytokine combinations in immunotherapy for solid tumors: a review. Cancer Immunol Immunother 1993; 37: 243-249.
48. Gansbacher B, Zier K, Daniels B et al. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172: 1217-1224.
49. Talmadge JE. The pharmaceutics and delivery of therapeutic polypeptide proteins. Adv Drug Delhi Rev 1993; 10: 247-299.